Low risk of hemorrhagic complications after obtaining diagnostic skin biopsy specimens in a cohort of thrombocytopenic inpatients To the Editor: Previous studies evaluating inpatient diagnostic skin biopsies have determined minimal risk for hematomas in noncoagulopathic patients. 1 However, the risk of bleeding after skin biopsies in thrombocytopenic patients or those with other bleeding risk factors remains unknown. In this study, we evaluated hemorrhagic complications after skin biopsy in high-risk patients.
We searched the Research Patient Data Registry, a database containing records of patients from Brigham and Women's Hospital and Massachusetts General Hospital to identify inpatients who had skin biopsies between 2000 and 2015. Of 2878 patients, 300 were randomly selected with platelets #150,000/L, with 50% having platelets #20,000/ L and 50% having platelets between 20,000/L and 150,000/L. Patients without documentation of procedure details (n ¼ 91), without thrombocytopenia (n ¼ 1), or without a bedside skin biopsy (n ¼ 3) were excluded. Bleeding complications were defined as any bleeding during the hospitalization that required clinical intervention. The rate of bleeding complications was compared to published data on bleeding risks in nonthrombocytopenic patients (0%) after diagnostic skin biopsy. 1 We hypothesized a similarly low incidence among thrombocytopenic patients. As such, sample size was determined to achieve 80% power to detect equivalence to a rate of 1% bleeding complications with a range of 0% to 5%.
A total of 205 patients met the inclusion criteria (Table I) . One bleeding complication was identified in a patient with a 4-mm punch biopsy obtained from the calf by the primary (nondermatology) team that was left to heal by secondary intention. The patient had oozing at the biopsy site on the day of the biopsy procedure, which was stopped with pressure dressing. The total estimated blood loss was \25 mL. The patient had acute myeloid leukemia and a platelet count of 62,000/L. She was not taking any anticoagulants and lacked other risk factors for bleeding.
There were no other bleeding complications (Table II) . The bleeding complication rate of 1 out of 205 (0.49%) was not statistically different from the bleeding complication rate of 0% in nonthrombocytopenic patients (P ¼ .48). 1 We conclude that there is a low bleeding complication rate (0.49%) for diagnostic skin biopsies performed on inpatients with thrombocytopenia. The single bleeding complication was minor and occurred in a patient whose biopsy site was not sutured. This rate is statistically similar to the published data on bleeding risk after inpatient diagnostic skin biopsies in nonthrombocytopenic patients. 1 Bleeding risks were minimal in thrombocytopenic patients who were anticoagulated or had recent bleeding. Although 24 (11.7%) of patients received platelet transfusions on the day of the biopsy, 23 were transfused per protocol (not as prophylaxis) and had low platelets at the time of biopsy, suggesting that the impact of transfusion on overall bleeding risk was low.
Guidelines for skin biopsies in thrombocytopenic patients are limited and varied. 2, 3 Our data suggest that bleeding risks in patients whose platelet levels are \20,000/L are low, because none of the 75 patients with platelets #20,000/L had bleeding complications. This finding should diminish physician discomfort regarding skin biopsies in thrombocytopenic patients and reduce individual and institutional variability regarding platelet thresholds required to perform skin biopsies. 
